Analysts See $-0.18 EPS for Vascular Biogenics Ltd. (VBLT)

August 10, 2018 - By Billy Entrekin

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

Analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT) to report $-0.18 EPS on August, 16 before the open.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.18 EPS. After having $-0.24 EPS previously, Vascular Biogenics Ltd.’s analysts see -25.00 % EPS growth. It closed at $1.7 lastly. It is down 60.91% since August 10, 2017 and is downtrending. It has underperformed by 73.48% the S&P500.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 4 analysts covering Vascular Biogenics (NASDAQ:VBLT), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Vascular Biogenics had 6 analyst reports since March 8, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Hold” on Thursday, March 22. The rating was downgraded by H.C. Wainwright on Thursday, March 8 to “Neutral”. The firm has “Neutral” rating given on Friday, March 9 by Chardan Capital Markets. The stock has “Hold” rating by H.C. Wainwright on Friday, May 18. The firm earned “Hold” rating on Thursday, March 8 by Piper Jaffray. The firm earned “Hold” rating on Thursday, March 8 by JMP Securities.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $60.95 million. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

More recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict” on August 08, 2018. Also Benzinga.com published the news titled: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” on August 07, 2018. Globenewswire.com‘s news article titled: “VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16” with publication date: August 01, 2018 was also an interesting one.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.